Natera (NASDAQ:NTRA) Posts Earnings Results, Beats Expectations By $0.01 EPS

Natera (NASDAQ:NTRA) released its earnings results on Thursday. The medical research company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01, Zacks reports. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera updated its FY 2025 guidance to EPS.

Natera Stock Down 2.5 %

Natera stock opened at $156.61 on Friday. The firm has a market cap of $20.68 billion, a PE ratio of -88.98 and a beta of 1.66. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm’s 50 day moving average price is $167.59 and its two-hundred day moving average price is $146.60. Natera has a twelve month low of $75.18 and a twelve month high of $183.00.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research reports. The Goldman Sachs Group boosted their target price on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Barclays initiated coverage on shares of Natera in a report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price on the stock. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Sanford C. Bernstein boosted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, January 10th. Finally, Guggenheim boosted their price target on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $170.94.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 4,858 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $166.59, for a total value of $809,294.22. Following the completion of the sale, the insider now directly owns 114,912 shares of the company’s stock, valued at $19,143,190.08. The trade was a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 295,772 shares of company stock worth $49,741,699. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.